| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H23ClO2 |
| Molecular Weight | 378.891 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3
InChI
InChIKey=LUMKNAVTFCDUIE-VHXPQNKSSA-N
InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
| Molecular Formula | C24H23ClO2 |
| Molecular Weight | 378.891 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Ospemifene (commercial name Osphena produced by Shionogi) is anoral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) that selectively binds to estrogen receptors and either stimulates or blocks estrogen's activity in different tissue types. It has an agonistic effect on the endometrium. It’s building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulval and vaginal atrophy”.
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Sourcing
Sample Use Guides
Showing 1 to 5 of 10 entries
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
4-hydroxyospemifene (M1) is the major metabolite with a serum concentration of approximately 25% of ospemifene.
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
4’-hydroxyospemifene (M2) is the major metabolite with a serum concentration of approximately 7% of ospemifene.
MAJOR
|
Showing 1 to 5 of 5 entries
